Cancer Medicine
Open Access
ORIGINAL RESEARCH
TEM1 expression in cancer-associated fibroblasts is correlated with a poor prognosis in patients with gastric cancer Satoshi Fujii1,a, Ayano Fujihara1,a, Kei Natori1, Anna Abe1, Yasutoshi Kuboki1, Youichi Higuchi1, Masaki Aizawa2, Takeshi Kuwata1, Takahiro Kinoshita3, Wataru Yasui4 & Atsushi Ochiai1 1Pathology
Division, Research Center for Innovative Oncology National Cancer Center at Kashiwa, National Cancer Center Hospital East6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan 2Department of Digestive Surgery, Niigata Cancer Center Hospital2-15-3 Kawagishicho, Chuou-ku, Niigata 951-8566, Japan 3Department of Surgical Oncology, National Cancer Center Hospital East6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan 4Department of Molecular Pathology, Hiroshima University Institute of Biomedical and Health Sciences, Minami‑ku, Hiroshima 734-8551, Japan
Keywords Cancer stromal cell, cancer-associated fibroblast, gastric cancer, immunohistochemistry, TEM1 Correspondence Satoshi Fujii or Atsushi Ochiai, Pathology Division, Research Center for Innovative Oncology National Cancer Center at Kashiwa, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan. Tel: +81-3-7133-1111; Fax: +81-4-71346865; E-mail: [email protected] or [email protected] Funding Information This work was supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan (26460482), to S.F. Received: 19 December 2014; Revised: 18 February 2015; Accepted: 27 July 2015
Cancer Medicine 2015, 4(11):1667–1678 doi: 10.1002/cam4.515 aThese
Abstract The cancer stroma, including cancer-associated fibroblasts (CAFs), is known to contribute to cancer cell progression and metastasis, suggesting that functional proteins expressed specifically in CAFs might be candidate molecular targets for cancer treatment. The purpose of the present study was to explore the possibility of using TEM1 (tumor endothelial marker 1), which is known to be expressed in several types of mesenchymal cells, as a molecular target by examining the impact of TEM1 expression on clinicopathological factors in gastric cancer patients. A total of 945 consecutive patients with gastric cancer who underwent surgery at the National Cancer Center Hospital East between January 2003 and July 2007 were examined using a tissue microarray approach. TEM1 expression in CAFs or vessel-associated cells was determined using immunohistochemical staining. Three items (CAF-TEM1-positivity, CAF-TEM1-intensity, and vessel-TEM1-intensity) were then examined to determine the correlations between the TEM1 expression status and the recurrence- free survival (RFS), overall survival (OS), cancer-related survival (COS), and other clinicopathological factors. Significant correlations between CAF-TEM1-positivity or CAF-TEM1- intensity and RFS, OS, or COS were observed (P
Open Access
ORIGINAL RESEARCH
TEM1 expression in cancer-associated fibroblasts is correlated with a poor prognosis in patients with gastric cancer Satoshi Fujii1,a, Ayano Fujihara1,a, Kei Natori1, Anna Abe1, Yasutoshi Kuboki1, Youichi Higuchi1, Masaki Aizawa2, Takeshi Kuwata1, Takahiro Kinoshita3, Wataru Yasui4 & Atsushi Ochiai1 1Pathology
Division, Research Center for Innovative Oncology National Cancer Center at Kashiwa, National Cancer Center Hospital East6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan 2Department of Digestive Surgery, Niigata Cancer Center Hospital2-15-3 Kawagishicho, Chuou-ku, Niigata 951-8566, Japan 3Department of Surgical Oncology, National Cancer Center Hospital East6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan 4Department of Molecular Pathology, Hiroshima University Institute of Biomedical and Health Sciences, Minami‑ku, Hiroshima 734-8551, Japan
Keywords Cancer stromal cell, cancer-associated fibroblast, gastric cancer, immunohistochemistry, TEM1 Correspondence Satoshi Fujii or Atsushi Ochiai, Pathology Division, Research Center for Innovative Oncology National Cancer Center at Kashiwa, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan. Tel: +81-3-7133-1111; Fax: +81-4-71346865; E-mail: [email protected] or [email protected] Funding Information This work was supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan (26460482), to S.F. Received: 19 December 2014; Revised: 18 February 2015; Accepted: 27 July 2015
Cancer Medicine 2015, 4(11):1667–1678 doi: 10.1002/cam4.515 aThese
Abstract The cancer stroma, including cancer-associated fibroblasts (CAFs), is known to contribute to cancer cell progression and metastasis, suggesting that functional proteins expressed specifically in CAFs might be candidate molecular targets for cancer treatment. The purpose of the present study was to explore the possibility of using TEM1 (tumor endothelial marker 1), which is known to be expressed in several types of mesenchymal cells, as a molecular target by examining the impact of TEM1 expression on clinicopathological factors in gastric cancer patients. A total of 945 consecutive patients with gastric cancer who underwent surgery at the National Cancer Center Hospital East between January 2003 and July 2007 were examined using a tissue microarray approach. TEM1 expression in CAFs or vessel-associated cells was determined using immunohistochemical staining. Three items (CAF-TEM1-positivity, CAF-TEM1-intensity, and vessel-TEM1-intensity) were then examined to determine the correlations between the TEM1 expression status and the recurrence- free survival (RFS), overall survival (OS), cancer-related survival (COS), and other clinicopathological factors. Significant correlations between CAF-TEM1-positivity or CAF-TEM1- intensity and RFS, OS, or COS were observed (P
